Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/62296
Título: | A recombinant rabies virus expressing the Marburg Virus Glycoprotein Is dependent upon ADCC for protection against Marburg Virus Disease in a Murine Model |
Autor(es): | Keshwara, Rohan Hagen, Katie R. Abreu-Mota, Tiago Papaneri, Amy B. Liu, David Wirblich, Christoph Johnson, Reed F. Schnell, Matthias J. |
Palavras-chave: | Animals Antibodies, Neutralizing Antibodies, Viral Cell Line Cercopithecus aethiops Disease Models, Animal Female Glycoproteins HEK293 Cells Humans Marburg Virus Disease Marburgvirus Mice Mice, Inbred BALB C Mice, Inbred C57BL Rabies Rabies Vaccines Rabies virus Vaccination Vero Cells Viral Vaccines ADCC antibody function filovirus immunization vaccine |
Data: | 2019 |
Editora: | American Society for Microbiology |
Revista: | Journal of Virology |
Citação: | Keshwara, R., Hagen, K. R., Abreu-Mota, T., et. al. (2019). A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model. Journal of virology, 93(6), e01865-18. |
Resumo(s): | Marburg virus (MARV) is a filovirus related to Ebola virus (EBOV) associated with human hemorrhagic disease. Outbreaks are sporadic and severe, with a reported case mortality rate of upward of 88%. There is currently no antiviral or vaccine available. Given the sporadic nature of outbreaks, vaccines provide the best approach for long-term control of MARV in regions of endemicity. We have developed an inactivated rabies virus-vectored MARV vaccine (FILORAB3) to protect against Marburg virus disease. Immunogenicity studies in our labs have shown that a Th1-biased seroconversion to both rabies virus and MARV glycoproteins (GPs) is beneficial for protection in a preclinical murine model. As such, we adjuvanted FILORAB3 with glucopyranosyl lipid adjuvant (GLA), a Toll-like receptor 4 agonist, in a squalene-in-water emulsion. Across two different BALB/c mouse challenge models, we achieved 92% protection against murine-adapted Marburg virus (ma-MARV). Although our vaccine elicited strong MARV GP antibodies, it did not strongly induce neutralizing antibodies. Through both in vitro and in vivo approaches, we elucidated a critical role for NK cell-dependent antibody-mediated cellular cytotoxicity (ADCC) in vaccine-induced protection. Overall, these findings demonstrate that FILORAB3 is a promising vaccine candidate for Marburg virus disease.IMPORTANCE Marburg virus (MARV) is a virus similar to Ebola virus and also causes a hemorrhagic disease which is highly lethal. In contrast to EBOV, only a few vaccines have been developed against MARV, and researchers do not understand what kind of immune responses are required to protect from MARV. Here we show that antibodies directed against MARV after application of our vaccine protect in an animal system but fail to neutralize the virus in a widely used virus neutralization assay against MARV. This newly discovered activity needs to be considered more when analyzing MARV vaccines or infections. |
Tipo: | Artigo |
Descrição: | Accepted Manuscript |
URI: | https://hdl.handle.net/1822/62296 |
DOI: | 10.1128/JVI.01865-18 |
ISSN: | 0022-538X |
e-ISSN: | 1098-5514 |
Versão da editora: | https://jvi.asm.org/content/93/6/e01865-18.abstract |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Keshwara R et al. J Virol.pdf | 634,57 kB | Adobe PDF | Ver/Abrir |